{"transactions":[{"id":837186,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-18T01:00:11.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":690950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-26-009899","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126009899/form4.xml","form_type":"4"}},{"id":837185,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-18T01:00:11.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":15.16,"value":90960.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2112777,"source":{"system":"sec-edgar","filing":"0001140361-26-009899","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126009899/form4.xml","form_type":"4"}},{"id":837184,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-18T01:00:11.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":15.16,"value":227400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2118777,"source":{"system":"sec-edgar","filing":"0001140361-26-009899","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126009899/form4.xml","form_type":"4"}},{"id":837183,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-18T01:00:11.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."}],"balance_after":2133777,"source":{"system":"sec-edgar","filing":"0001140361-26-009899","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126009899/form4.xml","form_type":"4"}},{"id":850475,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-11T01:00:06.000Z","date":"2026-03-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":29513,"price":15.39,"value":454205.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) and (v) 1,224,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2118777,"source":{"system":"sec-edgar","filing":"0001140361-26-008904","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126008904/form4.xml","form_type":"4"}},{"id":850474,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-11T01:00:06.000Z","date":"2026-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":56438,"price":15.39,"value":868580.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."}],"balance_after":2148290,"source":{"system":"sec-edgar","filing":"0001140361-26-008904","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126008904/form4.xml","form_type":"4"}},{"id":873679,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-03T02:00:14.000Z","date":"2026-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":54858,"price":15.18,"value":832744.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,092,470 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2204728,"source":{"system":"sec-edgar","filing":"0001140361-26-007406","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126007406/form4.xml","form_type":"4"}},{"id":887657,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-24T02:00:18.000Z","date":"2026-02-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":24793,"price":16.32,"value":404621.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,007,896 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2259586,"source":{"system":"sec-edgar","filing":"0001140361-26-006461","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126006461/form4.xml","form_type":"4"}},{"id":900453,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T02:39:40.000Z","date":"2026-02-17","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":705950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-26-005888","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126005888/form4.xml","form_type":"4"}},{"id":900452,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-18T02:39:40.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":16.08,"value":96480.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 969,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2284379,"source":{"system":"sec-edgar","filing":"0001140361-26-005888","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126005888/form4.xml","form_type":"4"}},{"id":900451,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-18T02:39:40.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16.08,"value":241200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2290379,"source":{"system":"sec-edgar","filing":"0001140361-26-005888","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126005888/form4.xml","form_type":"4"}},{"id":900450,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-18T02:39:40.000Z","date":"2026-02-17","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025."}],"balance_after":2305379,"source":{"system":"sec-edgar","filing":"0001140361-26-005888","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126005888/form4.xml","form_type":"4"}},{"id":909614,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-12T02:00:19.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":444711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan."}],"balance_after":444711,"derivative":{"exercise_price":16.37,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":444711},"source":{"system":"sec-edgar","filing":"0001140361-26-004890","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126004890/form4.xml","form_type":"4"}},{"id":909613,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-12T02:00:19.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":282529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the \"Plan\"), subject to the Reporting Person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2290379,"source":{"system":"sec-edgar","filing":"0001140361-26-004890","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126004890/form4.xml","form_type":"4"}},{"id":967197,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-17T02:00:23.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":720950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-045737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125045737/form4.xml","form_type":"4"}},{"id":967196,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-17T02:00:23.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":19.79,"value":118740.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 975,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2007850,"source":{"system":"sec-edgar","filing":"0001140361-25-045737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125045737/form4.xml","form_type":"4"}},{"id":967195,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-17T02:00:23.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":19.79,"value":296850.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2013850,"source":{"system":"sec-edgar","filing":"0001140361-25-045737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125045737/form4.xml","form_type":"4"}},{"id":967194,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-17T02:00:23.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2028850,"source":{"system":"sec-edgar","filing":"0001140361-25-045737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125045737/form4.xml","form_type":"4"}},{"id":991112,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-22T02:00:37.000Z","date":"2025-11-19","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":735950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-042997","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125042997/form4.xml","form_type":"4"}},{"id":991111,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-22T02:00:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":16,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 981,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2013850,"source":{"system":"sec-edgar","filing":"0001140361-25-042997","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125042997/form4.xml","form_type":"4"}},{"id":991110,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-22T02:00:37.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16,"value":240000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2019850,"source":{"system":"sec-edgar","filing":"0001140361-25-042997","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125042997/form4.xml","form_type":"4"}},{"id":991109,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-22T02:00:37.000Z","date":"2025-11-19","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2034850,"source":{"system":"sec-edgar","filing":"0001140361-25-042997","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125042997/form4.xml","form_type":"4"}},{"id":1013751,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-25T01:05:36.000Z","date":"2025-10-24","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":750950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-039331","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125039331/form4.xml","form_type":"4"}},{"id":1013750,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-25T01:05:36.000Z","date":"2025-10-24","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":16,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 987,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2019850,"source":{"system":"sec-edgar","filing":"0001140361-25-039331","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125039331/form4.xml","form_type":"4"}},{"id":1013749,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-25T01:05:36.000Z","date":"2025-10-24","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16,"value":240000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2025850,"source":{"system":"sec-edgar","filing":"0001140361-25-039331","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125039331/form4.xml","form_type":"4"}},{"id":1013748,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-25T01:05:36.000Z","date":"2025-10-24","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2040850,"source":{"system":"sec-edgar","filing":"0001140361-25-039331","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125039331/form4.xml","form_type":"4"}},{"id":1039108,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-09-17T01:00:11.000Z","date":"2025-09-15","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":765950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-035159","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125035159/form4.xml","form_type":"4"}},{"id":1039107,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-17T01:00:11.000Z","date":"2025-09-15","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":16.13,"value":96780.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 993,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2025850,"source":{"system":"sec-edgar","filing":"0001140361-25-035159","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125035159/form4.xml","form_type":"4"}},{"id":1039106,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-17T01:00:11.000Z","date":"2025-09-15","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16.13,"value":241950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2031850,"source":{"system":"sec-edgar","filing":"0001140361-25-035159","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125035159/form4.xml","form_type":"4"}},{"id":1039105,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-17T01:00:11.000Z","date":"2025-09-15","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2046850,"source":{"system":"sec-edgar","filing":"0001140361-25-035159","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125035159/form4.xml","form_type":"4"}},{"id":1065100,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-16T01:00:22.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":780950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-031601","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125031601/form4.xml","form_type":"4"}},{"id":1065099,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-16T01:00:22.000Z","date":"2025-08-15","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":16.88,"value":101280.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 999,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2031850,"source":{"system":"sec-edgar","filing":"0001140361-25-031601","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125031601/form4.xml","form_type":"4"}},{"id":1065098,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-16T01:00:22.000Z","date":"2025-08-15","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16.88,"value":253200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2037850,"source":{"system":"sec-edgar","filing":"0001140361-25-031601","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125031601/form4.xml","form_type":"4"}},{"id":1065097,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-16T01:00:22.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2052850,"source":{"system":"sec-edgar","filing":"0001140361-25-031601","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125031601/form4.xml","form_type":"4"}},{"id":1086387,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-17T01:00:32.000Z","date":"2025-07-15","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":795950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-026099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125026099/form4.xml","form_type":"4"}},{"id":1086386,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-17T01:00:32.000Z","date":"2025-07-15","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":18.66,"value":111960.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,005,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2037850,"source":{"system":"sec-edgar","filing":"0001140361-25-026099","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125026099/form4.xml","form_type":"4"}},{"id":1086385,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-17T01:00:32.000Z","date":"2025-07-15","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":18.66,"value":279900.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2043850,"source":{"system":"sec-edgar","filing":"0001140361-25-026099","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125026099/form4.xml","form_type":"4"}},{"id":1086384,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-17T01:00:32.000Z","date":"2025-07-15","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2058850,"source":{"system":"sec-edgar","filing":"0001140361-25-026099","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125026099/form4.xml","form_type":"4"}},{"id":1106027,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-19T01:00:24.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":810950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-023017","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125023017/form4.xml","form_type":"4"}},{"id":1106026,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-19T01:00:24.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":20.81,"value":124860.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,011,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2043850,"source":{"system":"sec-edgar","filing":"0001140361-25-023017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125023017/form4.xml","form_type":"4"}},{"id":1106025,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-19T01:00:24.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":20.81,"value":312150.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2049850,"source":{"system":"sec-edgar","filing":"0001140361-25-023017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125023017/form4.xml","form_type":"4"}},{"id":1106024,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-19T01:00:24.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2064850,"source":{"system":"sec-edgar","filing":"0001140361-25-023017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125023017/form4.xml","form_type":"4"}},{"id":1144960,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-17T01:00:14.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":825950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-019589","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125019589/form4.xml","form_type":"4"}},{"id":1144959,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-17T01:00:14.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":19.45,"value":116700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,017,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2049850,"source":{"system":"sec-edgar","filing":"0001140361-25-019589","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125019589/form4.xml","form_type":"4"}},{"id":1144958,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-17T01:00:14.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":19.45,"value":291750.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2055850,"source":{"system":"sec-edgar","filing":"0001140361-25-019589","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125019589/form4.xml","form_type":"4"}},{"id":1144957,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-17T01:00:14.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2070850,"source":{"system":"sec-edgar","filing":"0001140361-25-019589","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125019589/form4.xml","form_type":"4"}},{"id":1170884,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T01:00:26.000Z","date":"2025-04-15","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":840950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-014267","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125014267/form4.xml","form_type":"4"}},{"id":1170883,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-04-17T01:00:26.000Z","date":"2025-04-15","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":21.46,"value":128760.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,023,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2055850,"source":{"system":"sec-edgar","filing":"0001140361-25-014267","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125014267/form4.xml","form_type":"4"}},{"id":1170882,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-04-17T01:00:26.000Z","date":"2025-04-15","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":21.46,"value":321900.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2061850,"source":{"system":"sec-edgar","filing":"0001140361-25-014267","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125014267/form4.xml","form_type":"4"}},{"id":1170881,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-04-17T01:00:26.000Z","date":"2025-04-15","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2076850,"source":{"system":"sec-edgar","filing":"0001140361-25-014267","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125014267/form4.xml","form_type":"4"}},{"id":1194497,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-22T01:00:15.000Z","date":"2025-03-19","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028."}],"balance_after":855950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-009928","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125009928/form4.xml","form_type":"4"}},{"id":1194496,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-22T01:00:15.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":18.92,"value":113520.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,029,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2061850,"source":{"system":"sec-edgar","filing":"0001140361-25-009928","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125009928/form4.xml","form_type":"4"}},{"id":1194495,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-22T01:00:15.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":18.92,"value":283800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the price at which the shares were sold."}],"balance_after":2067850,"source":{"system":"sec-edgar","filing":"0001140361-25-009928","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125009928/form4.xml","form_type":"4"}},{"id":1194494,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-22T01:00:15.000Z","date":"2025-03-19","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":5.4,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer."}],"balance_after":2082850,"source":{"system":"sec-edgar","filing":"0001140361-25-009928","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125009928/form4.xml","form_type":"4"}},{"id":1214668,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-11T01:00:26.000Z","date":"2025-03-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":29513,"price":17.02,"value":502311.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,035,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2067850,"source":{"system":"sec-edgar","filing":"0001140361-25-007924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125007924/form4.xml","form_type":"4"}},{"id":1214667,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-11T01:00:26.000Z","date":"2025-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":56438,"price":16.91,"value":954366.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 990,197 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2097363,"source":{"system":"sec-edgar","filing":"0001140361-25-007924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125007924/form4.xml","form_type":"4"}},{"id":1240361,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-28T02:00:24.000Z","date":"2025-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":54867,"price":15.78,"value":865801.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"(continued from footnote 5) and (v) 903,211 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2153801,"source":{"system":"sec-edgar","filing":"0001140361-25-006386","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125006386/form4.xml","form_type":"4"}},{"id":1240360,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-28T02:00:24.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":18018,"price":15.44,"value":278197.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 818,646 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2208668,"source":{"system":"sec-edgar","filing":"0001140361-25-006386","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125006386/form4.xml","form_type":"4"}},{"id":1252439,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-22T02:01:52.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":376744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan."}],"balance_after":376744,"derivative":{"exercise_price":16.07,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":376744},"source":{"system":"sec-edgar","filing":"0001140361-25-005534","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125005534/form4.xml","form_type":"4"}},{"id":1252438,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-22T02:01:52.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":252022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the \"Plan\"), subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) and (vi) 790,876 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2226686,"source":{"system":"sec-edgar","filing":"0001140361-25-005534","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125005534/form4.xml","form_type":"4"}},{"id":1313883,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-04T02:00:26.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":14343,"price":17.15,"value":245982.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (\"RSUs\"). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting; and (v) 790,876 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1974664,"source":{"system":"sec-edgar","filing":"0001140361-25-000270","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125000270/form4.xml","form_type":"4"}},{"id":1353903,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-23T02:05:13.000Z","date":"2024-11-22","kind":"sale","planned":false,"acquired":false,"shares":48967,"price":21.1,"value":1033203.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that were granted on September 29, 2021 and vested on June 30, 2024 and September 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.13. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 557,728 restricted stock units (\"RSUs\") granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 56,719 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) and (vi) 748,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":1989007,"source":{"system":"sec-edgar","filing":"0001140361-24-047701","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124047701/form4.xml","form_type":"4"}},{"id":1393857,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-03T01:00:35.000Z","date":"2024-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":21752,"price":19.99,"value":434822.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 557,728 restricted stock units (\"RSUs\") granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 56,719 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) and (vi) 797,467 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2037974,"source":{"system":"sec-edgar","filing":"0001140361-24-042641","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124042641/form4.xml","form_type":"4"}},{"id":1421732,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":false,"shares":47396,"price":2.915,"value":138159.34,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"These options were granted on February 28, 2020 and vested over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024."}],"balance_after":0,"derivative":{"exercise_price":2.915,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":47396},"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421731,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":false,"shares":341960,"price":3.35,"value":1145566.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options were granted on March 6, 2023 and vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027."}],"balance_after":741020,"derivative":{"exercise_price":3.35,"expiration_date":"2033-03-06","underlying":"Common Stock","underlying_shares":341960},"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421730,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":false,"shares":60000,"price":10.8,"value":648000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F14","text":"The Reporting Person is exercising these options due, in part, to their near-term expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"These options were granted on January 30, 2015 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on January 30, 2019."}],"balance_after":0,"derivative":{"exercise_price":10.8,"expiration_date":"2025-01-30","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421729,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":false,"shares":40500,"price":9.37,"value":379485.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F14","text":"The Reporting Person is exercising these options due, in part, to their near-term expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"These options were granted on October 9, 2015 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on October 9, 2019."}],"balance_after":0,"derivative":{"exercise_price":9.37,"expiration_date":"2025-10-09","underlying":"Common Stock","underlying_shares":40500},"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421728,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":false,"shares":16984,"price":5.96,"value":101224.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F14","text":"The Reporting Person is exercising these options due, in part, to their near-term expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"These options were granted on January 28, 2016 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on January 28, 2020."}],"balance_after":0,"derivative":{"exercise_price":5.96,"expiration_date":"2026-01-28","underlying":"Common Stock","underlying_shares":16984},"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421727,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":false,"shares":55000,"price":5,"value":275000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These options were granted on February 14, 2017 and vested over four years with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421726,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":false,"shares":64405,"price":3.35,"value":215756.75,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options were granted on March 6, 2023 and vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027."}],"balance_after":1082980,"derivative":{"exercise_price":3.35,"expiration_date":"2033-03-06","underlying":"Common Stock","underlying_shares":64405},"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421725,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":389356,"price":17.2924,"value":6732899.6944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.375. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 557,728 restricted stock units (\"RSUs\") granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 113,438 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) and (vi) 762,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2059726,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421724,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":true,"shares":47396,"price":2.915,"value":138159.34,"ownership":{"direct":true},"balance_after":2449082,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421723,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":true,"shares":341960,"price":3.35,"value":1145566.0,"ownership":{"direct":true},"balance_after":2401686,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421722,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":236889,"price":17.6922,"value":4191087.5658,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.45. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2059726,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421721,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":true,"shares":60000,"price":10.8,"value":648000.0,"ownership":{"direct":true},"balance_after":2296615,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421720,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":true,"shares":40500,"price":9.37,"value":379485.0,"ownership":{"direct":true},"balance_after":2236615,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421719,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":true,"shares":16984,"price":5.96,"value":101224.64,"ownership":{"direct":true},"balance_after":2196115,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421718,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":true,"shares":55000,"price":5,"value":275000.0,"ownership":{"direct":true},"balance_after":2179131,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1421717,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T01:22:44.000Z","date":"2024-08-26","kind":"exercise","planned":false,"acquired":true,"shares":64405,"price":3.35,"value":215756.75,"ownership":{"direct":true},"balance_after":2124131,"source":{"system":"sec-edgar","filing":"0001140361-24-038772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124038772/form4.xml","form_type":"4"}},{"id":1462279,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President,CEO, and Interim CFO"}}],"security":"Common Stock","published_at":"2024-07-03T01:00:19.000Z","date":"2024-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":21752,"price":11.18,"value":243187.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 113,438 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) and (vi) 762,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2059726,"source":{"system":"sec-edgar","filing":"0001140361-24-032245","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124032245/form4.xml","form_type":"4"}},{"id":1478643,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President,CEO, and Interim CFO"}}],"security":"Common Stock","published_at":"2024-06-15T01:00:42.000Z","date":"2024-06-14","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":10.7198,"value":1071980.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"These shares were sold by the reporting person in connection with the Divorce Settlement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) and (vi) 727,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2081475,"source":{"system":"sec-edgar","filing":"0001140361-24-030232","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124030232/form4.xml","form_type":"4"}},{"id":1478642,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President,CEO, and Interim CFO"}}],"security":"Common Stock","published_at":"2024-06-15T01:00:42.000Z","date":"2024-06-14","kind":"gift","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The shares were transferred by the reporting person to a third party in connection with the Divorce Settlement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) and (vi) 727,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2181475,"source":{"system":"sec-edgar","filing":"0001140361-24-030232","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124030232/form4.xml","form_type":"4"}},{"id":1478641,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President,CEO, and Interim CFO"}}],"security":"Common Stock","published_at":"2024-06-15T01:00:42.000Z","date":"2024-06-14","kind":"other","planned":false,"acquired":false,"shares":460000,"price":3.21,"value":1476600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the \"Divorce Settlement\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) and (vi) 727,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2191475,"source":{"system":"sec-edgar","filing":"0001140361-24-030232","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124030232/form4.xml","form_type":"4"}},{"id":1552884,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President,CEO, and Interim CFO"}}],"security":"Common Stock","published_at":"2024-04-03T01:00:39.000Z","date":"2024-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":21752,"price":6.6,"value":143563.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) and (vi) 1,297,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2651475,"source":{"system":"sec-edgar","filing":"0001140361-24-017376","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124017376/form4.xml","form_type":"4"}},{"id":1586171,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-09T02:00:40.000Z","date":"2024-03-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":28763,"price":6.16,"value":177180.08,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 2) (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 3) and (vi) 1,262,567 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2673227,"source":{"system":"sec-edgar","filing":"0001140361-24-012445","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124012445/form4.xml","form_type":"4"}},{"id":1586170,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-09T02:00:40.000Z","date":"2024-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":55003,"price":6.12,"value":336618.36,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 2) (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 3) and (vi) 1,262,567 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2701990,"source":{"system":"sec-edgar","filing":"0001140361-24-012445","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124012445/form4.xml","form_type":"4"}},{"id":1602539,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T02:00:34.000Z","date":"2024-02-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":9588,"price":5.36,"value":51391.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) and (vi) 1,127,910 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2756993,"source":{"system":"sec-edgar","filing":"0001140361-24-011194","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124011194/form4.xml","form_type":"4"}},{"id":1611851,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-29T02:00:49.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":870950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests over four years with 25% of the shares of Common Stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028 in accordance with the Plan."}],"balance_after":870950,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":870950},"source":{"system":"sec-edgar","filing":"0001140361-24-010243","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010243/form4.xml","form_type":"4"}},{"id":1611850,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-29T02:00:49.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":557728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest quarterly on each three-month anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the \"Plan\"), subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) and (vi) 1,137,498 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2766581,"source":{"system":"sec-edgar","filing":"0001140361-24-010243","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010243/form4.xml","form_type":"4"}},{"id":1614837,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-28T02:00:25.000Z","date":"2024-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":22457,"price":5.26,"value":118123.82,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 45,785 unvested RSUs granted on February 25, 2021, of which 45,788 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,112,498 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2208853,"source":{"system":"sec-edgar","filing":"0001140361-24-009842","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124009842/form4.xml","form_type":"4"}},{"id":1685264,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-06T02:00:26.000Z","date":"2023-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":23057,"price":4.52,"value":104217.64,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,076,399 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2231310,"source":{"system":"sec-edgar","filing":"0001140361-24-001138","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124001138/form4.xml","form_type":"4"}},{"id":1766752,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-04T01:02:41.000Z","date":"2023-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":18718,"price":3.58,"value":67010.44,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 283,594 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,042,737 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2254367,"source":{"system":"sec-edgar","filing":"0001140361-23-046743","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123046743/form4.xml","form_type":"4"}},{"id":1801685,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-19T01:46:47.000Z","date":"2023-08-18","kind":"sale","planned":false,"acquired":false,"shares":250000,"price":4.1534,"value":1038350.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price of sales on August 18, 2023. The shares were sold in multiple transactions at prices ranging from $4.09 to $4.255, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,004,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2273085,"source":{"system":"sec-edgar","filing":"0001140361-23-040583","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040583/form4.xml","form_type":"4"}},{"id":1803095,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-18T01:30:51.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":583224,"price":3.66,"value":2134599.84,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021."}],"balance_after":0,"derivative":{"exercise_price":3.66,"expiration_date":"2027-06-06","underlying":"Common Stock","underlying_shares":583224},"source":{"system":"sec-edgar","filing":"0001140361-23-040322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040322/form4.xml","form_type":"4"}},{"id":1803094,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-18T01:30:51.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":350000,"price":3.71,"value":1298500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.71,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001140361-23-040322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040322/form4.xml","form_type":"4"}},{"id":1803093,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-18T01:30:51.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":400000,"price":3.22,"value":1288000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023"}],"balance_after":0,"derivative":{"exercise_price":3.22,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001140361-23-040322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040322/form4.xml","form_type":"4"}},{"id":1803092,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-18T01:30:51.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":277604,"price":2.915,"value":809215.66,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024."}],"balance_after":47396,"derivative":{"exercise_price":2.915,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":277604},"source":{"system":"sec-edgar","filing":"0001140361-23-040322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040322/form4.xml","form_type":"4"}},{"id":1803091,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-18T01:30:51.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":277131,"price":2.35,"value":651257.85,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025."}],"balance_after":181569,"derivative":{"exercise_price":2.35,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":277131},"source":{"system":"sec-edgar","filing":"0001140361-23-040322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040322/form4.xml","form_type":"4"}},{"id":1803090,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-18T01:30:51.000Z","date":"2023-08-15","kind":"exercise","planned":false,"acquired":false,"shares":212500,"price":1.67,"value":354875.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026."}],"balance_after":387500,"derivative":{"exercise_price":1.67,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":212500},"source":{"system":"sec-edgar","filing":"0001140361-23-040322","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040322/form4.xml","form_type":"4"}},{"id":1803089,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":59867,"kind":"person","name":"Grossman Adam S","position":1,"cik":"0001542517","reported_name":"Grossman Adam S","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-18T01:30:51.000Z","date":"2023-08-16","kind":"sale","planned":false,"acquired":false,"shares":3,"price":4.385,"value":13.155,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the \"Time-Based RSUs\") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,254,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes."}],"balance_after":2523085,"source":{"system":"sec-edgar","filing":"0001140361-23-040322","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123040322/form4.xml","form_type":"4"}}],"next_cursor":"2023-08-18T01:30:51.000000Z,1803089"}